Copenhagen, 2014-05-08 08:00 CEST (GLOBE NEWSWIRE) --
Performance for the period (unaudited)
(Comparative figures for 2013 are shown in brackets / revenue growth is measured in local currencies)
Revenue and operating profit (EBITDA) in Q1 was strong. In particular, performance of allergy immunotherapy products in Europe exceeded expectations.
Partner and pipeline activities in 2014
Significant progress in ALK’s work to globalise its product portfolio:
2014 financial guidance
Due to the better than expected performance in Q1, the outlook for 2014 is adjusted: Revenue, including milestone payments, is now expected to equal approximately DKK 2.4 billion before future income streams from product supply and sales royalties from SLIT-tablets in North America (previously DKK 2.15-2.2 billion before milestones and any other contribution from SLIT-tablets in North America). EBITDA is now expected at approximately DKK 425 million (previously 'up to 400') before special items and future income from product supply and sales royalties in North America.
Hørsholm, 8 May 2014
ALK-Abelló A/S
Contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Today, ALK hosts a conference call for analysts and investors at 12.30 p.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on www.alk-abello.com/investor. Participants in the audio cast are kindly requested to call in before 12.25 p.m. (CET). Danish participants should call in on tel. +45 70 25 23 00 or +45 70 25 67 00 and international participants should call in on tel. +44 (0) 208 817 9311. Please use the following Audience Passcode: 9575 3890#. The audio cast is available live on our website, where the related presentation will be available shortly before the call begins.